Literature DB >> 31929998

Stratification of risk of recurrence after curative-intent treatment for small hepatocellular carcinoma.

Junichi Shindoh1.   

Abstract

Entities:  

Year:  2019        PMID： 31929998      PMCID： PMC6943013          DOI： 10.21037/hbsn.2019.07.17

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  13 in total

1.  A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria.

Authors:  Jiwei Huang; Lvnan Yan; Zheyu Cheng; Hong Wu; Liang Du; Jinzhou Wang; Yinglong Xu; Yong Zeng
Journal:  Ann Surg       Date:  2010-12       Impact factor: 12.969

2.  Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines).

Authors:  Norihiro Kokudo; Kiyoshi Hasegawa; Masaaki Akahane; Hiroshi Igaki; Namiki Izumi; Takafumi Ichida; Shinji Uemoto; Shuichi Kaneko; Seiji Kawasaki; Yonson Ku; Masatoshi Kudo; Shoji Kubo; Tadatoshi Takayama; Ryosuke Tateishi; Takashi Fukuda; Osamu Matsui; Yutaka Matsuyama; Takamichi Murakami; Shigeki Arii; Masatoshi Okazaki; Masatoshi Makuuchi
Journal:  Hepatol Res       Date:  2015-01       Impact factor: 4.288

3.  Risk factors of post-operative recurrence and adequate surgical approach to improve long-term outcomes of hepatocellular carcinoma.

Authors:  Junichi Shindoh; Kiyoshi Hasegawa; Yosuke Inoue; Takeaki Ishizawa; Rihito Nagata; Taku Aoki; Yoshihiro Sakamoto; Yasuhiko Sugawara; Masatoshi Makuuchi; Norihiro Kokudo
Journal:  HPB (Oxford)       Date:  2012-08-26       Impact factor: 3.647

4.  Response to the Comment on "Effect of Microvascular Invasion Risk on Early Recurrence of Hepatocellular Carcinoma After Surgery and Radiofrequency Ablation".

Authors:  Sunyoung Lee; Tae Wook Kang
Journal:  Ann Surg       Date:  2021-07-01       Impact factor: 12.969

5.  A Clinical Scoring System for Predicting Microvascular Invasion in Patients with Hepatocellular Carcinoma Within the Milan Criteria.

Authors:  Tomoki Ryu; Yuko Takami; Yoshiyuki Wada; Masaki Tateishi; Takanobu Hara; Munehiro Yoshitomi; Seiya Momosaki; Kotaro Yasumori; Hideki Saitsu; Koji Okuda
Journal:  J Gastrointest Surg       Date:  2019-02-20       Impact factor: 3.452

6.  Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria.

Authors:  Kheng-Choon Lim; Pierce Kah-Hoe Chow; John C Allen; Ghim-Song Chia; Miaoshan Lim; Peng-Chung Cheow; Alexander Y F Chung; London L P Ooi; Say-Beng Tan
Journal:  Ann Surg       Date:  2011-07       Impact factor: 12.969

Review 7.  Systematic review of surgical resection vs radiofrequency ablation for hepatocellular carcinoma.

Authors:  Alessandro Cucchetti; Fabio Piscaglia; Matteo Cescon; Giorgio Ercolani; Antonio Daniele Pinna
Journal:  World J Gastroenterol       Date:  2013-07-14       Impact factor: 5.742

8.  A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma.

Authors:  Min-Shan Chen; Jin-Qing Li; Yun Zheng; Rong-Ping Guo; Hui-Hong Liang; Ya-Qi Zhang; Xiao-Jun Lin; Wan Y Lau
Journal:  Ann Surg       Date:  2006-03       Impact factor: 12.969

9.  The influence of histological differentiation grade on the outcome of liver resection for hepatocellular carcinomas 2 cm or smaller in size.

Authors:  Kazunari Sasaki; Masamichi Matsuda; Yu Ohkura; Yusuke Kawamura; Masafumi Inoue; Masaji Hashimoto; Kenji Ikeda; Hiromitsu Kumada; Goro Watanabe
Journal:  World J Surg       Date:  2015-05       Impact factor: 3.352

10.  A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma.

Authors:  Sasan Roayaie; Iris N Blume; Swan N Thung; Maria Guido; Maria-Isabel Fiel; Spiros Hiotis; Daniel M Labow; Josep M Llovet; Myron E Schwartz
Journal:  Gastroenterology       Date:  2009-06-12       Impact factor: 22.682
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.